Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entinostat + Erlotinib in Advanced NSCLC
NCT00602030Phase 2Completed
- Sponsor
- Syndax Pharmaceuticals
- Start
- Jan 2008
- Primary completion
- Feb 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of entinostat in non-small cell lung cancer (NSCLC) (5 arms), sponsored by Syndax Pharmaceuticals. Primary endpoints: Identification of Safe-dose for the Phase 2 Double-blind Phase at Cycle 1 and 4-Month Progression-free Survival Rate. Started Jan 2008; status: completed.
02
Drugs
entinostat
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00602030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00602030.